JNJ-42165279: Difference between revisions

Latest revision as of 11:43, 15 February 2025

Overview[edit]

JNJ-42165279 is a chemical compound that has been studied for its potential therapeutic effects in various neurological conditions. It is known to act as an inhibitor of the enzyme fatty acid amide hydrolase (FAAH), which is involved in the degradation of endocannabinoids such as anandamide. By inhibiting FAAH, JNJ-42165279 increases the levels of endocannabinoids, which can modulate pain, mood, and other physiological processes.

Mechanism of Action[edit]

JNJ-42165279 functions primarily as a selective inhibitor of FAAH. FAAH is an enzyme that breaks down fatty acid amides, including anandamide, a key endocannabinoid. By inhibiting FAAH, JNJ-42165279 prevents the breakdown of anandamide, leading to increased levels of this compound in the brain and other tissues. This elevation in anandamide levels can enhance the activation of cannabinoid receptors, particularly CB1 and CB2 receptors, which are involved in modulating pain, inflammation, and mood.

Potential Therapeutic Applications[edit]

The inhibition of FAAH by JNJ-42165279 has been explored for its potential benefits in treating various conditions, including:

Chronic Pain: By increasing endocannabinoid levels, JNJ-42165279 may help alleviate chronic pain conditions by modulating pain pathways in the central nervous system.
Anxiety Disorders: The anxiolytic effects of elevated anandamide levels could be beneficial in reducing symptoms of anxiety.
Depression: Modulation of the endocannabinoid system has been suggested to have antidepressant effects, making JNJ-42165279 a potential candidate for depression treatment.

Research and Development[edit]

Research on JNJ-42165279 has primarily been conducted in preclinical and early clinical settings. Studies have focused on its pharmacokinetics, safety profile, and efficacy in animal models of pain and anxiety. However, further research is needed to fully understand its therapeutic potential and safety in humans.

Related Pages[edit]

@@ Line 1: / Line 1: @@
-'''JNJ-42165279''' is an experimental drug developed by [[Janssen Pharmaceuticals]], a subsidiary of [[Johnson & Johnson]]. It is a selective antagonist of the [[fatty acid amide hydrolase]] (FAAH) enzyme, which is involved in the breakdown of [[endocannabinoids]] in the body. By inhibiting FAAH, JNJ-42165279 increases the levels of endocannabinoids, which are involved in a variety of physiological processes including pain, mood, and inflammation.
+{{DISPLAYTITLE:JNJ-42165279}}
-==Development and Clinical Trials==
+== Overview ==
-JNJ-42165279 has been investigated in several clinical trials for its potential therapeutic effects. In a Phase 2a study, the drug was found to be safe and well-tolerated in patients with [[social anxiety disorder]] and [[major depressive disorder]]. However, there were no significant differences in the primary efficacy endpoints between the JNJ-42165279 group and the placebo group.
+'''JNJ-42165279''' is a chemical compound that has been studied for its potential therapeutic effects in various neurological conditions. It is known to act as an inhibitor of the enzyme [[fatty acid amide hydrolase]] (FAAH), which is involved in the degradation of [[endocannabinoids]] such as [[anandamide]]. By inhibiting FAAH, JNJ-42165279 increases the levels of endocannabinoids, which can modulate pain, mood, and other physiological processes.
-In another Phase 2a study, JNJ-42165279 was evaluated in patients with [[neuropathic pain]] associated with [[small fiber neuropathy]]. The results of this study have not yet been published.
+== Mechanism of Action ==
+[[File:JNJ-42165279_Structure.svg|thumb|right|Chemical structure of JNJ-42165279]]
+JNJ-42165279 functions primarily as a selective inhibitor of FAAH. FAAH is an enzyme that breaks down fatty acid amides, including anandamide, a key endocannabinoid. By inhibiting FAAH, JNJ-42165279 prevents the breakdown of anandamide, leading to increased levels of this compound in the brain and other tissues. This elevation in anandamide levels can enhance the activation of [[cannabinoid receptors]], particularly [[CB1 receptor|CB1]] and [[CB2 receptor|CB2]] receptors, which are involved in modulating pain, inflammation, and mood.
-==Mechanism of Action==
+== Potential Therapeutic Applications ==
-JNJ-42165279 works by inhibiting the FAAH enzyme, which is responsible for breaking down endocannabinoids in the body. Endocannabinoids are naturally occurring compounds that bind to and activate [[cannabinoid receptors]]. These receptors are part of the [[endocannabinoid system]], which plays a key role in regulating a variety of physiological processes, including pain, mood, and inflammation. By inhibiting FAAH, JNJ-42165279 increases the levels of endocannabinoids, potentially enhancing the activity of the endocannabinoid system.
+The inhibition of FAAH by JNJ-42165279 has been explored for its potential benefits in treating various conditions, including:
-==Potential Therapeutic Applications==
+* '''Chronic Pain''': By increasing endocannabinoid levels, JNJ-42165279 may help alleviate chronic pain conditions by modulating pain pathways in the central nervous system.
-While the clinical trials conducted so far have not demonstrated significant efficacy of JNJ-42165279 in treating social anxiety disorder or major depressive disorder, the drug's mechanism of action suggests that it could potentially be useful in treating a variety of conditions associated with the endocannabinoid system. These could include chronic pain conditions, mood disorders, and inflammatory disorders. However, further research is needed to fully explore these potential applications.
+* '''Anxiety Disorders''': The anxiolytic effects of elevated anandamide levels could be beneficial in reducing symptoms of anxiety.
+* '''Depression''': Modulation of the endocannabinoid system has been suggested to have antidepressant effects, making JNJ-42165279 a potential candidate for depression treatment.
-==See Also==
+== Research and Development ==
+Research on JNJ-42165279 has primarily been conducted in preclinical and early clinical settings. Studies have focused on its pharmacokinetics, safety profile, and efficacy in animal models of pain and anxiety. However, further research is needed to fully understand its therapeutic potential and safety in humans.
+== Related Pages ==
 * [[Fatty acid amide hydrolase]]
 * [[Endocannabinoid system]]
-* [[Janssen Pharmaceuticals]]
+* [[Anandamide]]
-* [[Johnson & Johnson]]
+* [[Cannabinoid receptor]]
+[[Category:Pharmacology]]
 [[Category:Experimental drugs]]
-[[Category:Johnson & Johnson]]
-[[Category:Endocannabinoid system]]
-{{stub}}